Cetera Advisors LLC Has $1.87 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Cetera Advisors LLC lessened its holdings in Becton, Dickinson and Company (NYSE:BDXGet Rating) by 2.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,587 shares of the medical instruments supplier’s stock after selling 158 shares during the quarter. Cetera Advisors LLC’s holdings in Becton, Dickinson and were worth $1,871,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Core Alternative Capital boosted its holdings in shares of Becton, Dickinson and by 688.2% during the 1st quarter. Core Alternative Capital now owns 134 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 117 shares in the last quarter. McIlrath & Eck LLC boosted its holdings in shares of Becton, Dickinson and by 44.9% during the 1st quarter. McIlrath & Eck LLC now owns 142 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 44 shares in the last quarter. Crewe Advisors LLC acquired a new stake in shares of Becton, Dickinson and during the 2nd quarter valued at $43,000. Elequin Capital LP bought a new position in Becton, Dickinson and during the 1st quarter worth $45,000. Finally, Trustcore Financial Services LLC raised its position in Becton, Dickinson and by 1,346.2% during the 1st quarter. Trustcore Financial Services LLC now owns 188 shares of the medical instruments supplier’s stock worth $50,000 after purchasing an additional 175 shares during the last quarter. Institutional investors and hedge funds own 86.74% of the company’s stock.

Becton, Dickinson and Price Performance

BDX stock opened at $237.34 on Thursday. The company has a market capitalization of $67.69 billion, a P/E ratio of 40.36, a price-to-earnings-growth ratio of 2.69 and a beta of 0.61. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.63 and a current ratio of 1.04. Becton, Dickinson and Company has a 52-week low of $215.90 and a 52-week high of $280.62. The business has a 50-day simple moving average of $230.10 and a two-hundred day simple moving average of $243.16.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its earnings results on Thursday, November 10th. The medical instruments supplier reported $2.75 earnings per share for the quarter, topping analysts’ consensus estimates of $2.74 by $0.01. Becton, Dickinson and had a return on equity of 14.47% and a net margin of 9.16%. The firm had revenue of $4.76 billion for the quarter, compared to the consensus estimate of $4.72 billion. During the same quarter in the previous year, the business earned $2.15 EPS. The company’s revenue was down 6.6% compared to the same quarter last year. Research analysts expect that Becton, Dickinson and Company will post 11.94 EPS for the current fiscal year.

Becton, Dickinson and Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 30th. Stockholders of record on Friday, December 9th will be paid a $0.91 dividend. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.53%. The ex-dividend date is Thursday, December 8th. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.87. Becton, Dickinson and’s payout ratio is presently 59.18%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. William Blair reissued an “outperform” rating on shares of Becton, Dickinson and in a research report on Friday, November 11th. Morgan Stanley lifted their price objective on Becton, Dickinson and from $272.00 to $275.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 11th. StockNews.com lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Cowen lowered their price objective on Becton, Dickinson and to $255.00 in a research report on Wednesday, November 16th. Finally, The Goldman Sachs Group lowered their price objective on Becton, Dickinson and from $319.00 to $272.00 and set a “buy” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Becton, Dickinson and currently has an average rating of “Hold” and an average price target of $267.70.

Becton, Dickinson and Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.